The US Food and Drug Administration has cleared tralokinumab, an IL-3 inhibitor,  as a treatment for moderate to severe atopic dermatitis in adults who haven’t found appropriate solutions in topical subscription therapies. The approval comes after the drug, branded as Adbry, displayed clearance of skin lesions and reduction of itch after 16 weeks in recent trials. Tralokinumab developer Leo Pharma has said that it will roll out the drug commercially in February, positioning the brand against Sanofi and Regeneron’s Dupixent (dupilumab). Medical experts have pointed out that Adbry has a once-in-a-month injection time whereas Dupizent calls for dosing every two weeks for the patients.